Overview Dividends

(BWAY) Brainsway - Ratings and Ratios

Exchange: NASDAQ • Country: Israel • Currency: USD • Type: Common Stock • ISIN: US10501L1061

Deep Transcranial Magnetic Stimulation, Neurostimulation Platform

Health Care Equipment
Market Cap in USD: 318m

IPO / Inception: 1999-10-06
Return 12m vs S&P 500: 77.6%

EPS (Earnings per Share)

EPS CAGR: 7.31%
EPS Trend: 73.8%

Last SUE: -0.64
Qual. Beats: 0

Revenue

Rev. CAGR: 13.26%
Rev. Trend: 78.4%

Last SUE: 2.19
Qual. Beats: 2

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	58.2%
Value at Risk 5%th	86.5%
Relative Tail Risk	-9.66%

Reward TTM
Sharpe Ratio	1.66
Alpha	91.77
CAGR/Max DD	2.60

Character TTM
Hurst Exponent	0.547
Beta	0.917
Beta Downside	1.193

Drawdowns 3y
Max DD	40.89%
Mean DD	12.81%
Median DD	10.82%

Description: BWAY Brainsway October 28, 2025

BrainsWay Ltd. (NASDAQ:BWAY) commercializes a Deep Transcranial Magnetic Stimulation (dTMS) platform that delivers non-invasive neurostimulation for a broad spectrum of mental-health and neurological disorders, including major depressive disorder, obsessive-compulsive disorder, and post-traumatic stress disorder. The firm operates primarily in the United States, East Asia, and other international markets, selling its devices and treatment protocols to psychiatrists, hospitals, and medical centers. Founded in 2003 and headquartered in Jerusalem, Israel, BrainsWay is classified under the Health Care Equipment sub-industry.

Recent company filings suggest FY2023 revenue of roughly $30 million, with device shipments increasing about 15 % year-over-year-a sign that market adoption is accelerating despite the modest size of the overall TMS market. Independent industry analysts project the global TMS market to reach $2.5 billion by 2027, driven by expanding insurance reimbursement in the U.S. and rising mental-health spending worldwide; BrainsWay’s focus on a broader indication set (e.g., addiction, chronic pain) positions it to capture a larger share of this growth.

For a deeper quantitative assessment of BrainsWay’s valuation dynamics, you may find it useful to explore ValueRay’s analytical tools, which can help you model scenario-based outcomes and compare peer benchmarks.

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (6.25m TTM) > 0 and > 6% of Revenue (6% = 2.95m TTM)

FCFTA 0.16 (>2.0%) and ΔFCFTA 7.95pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 116.0% (prev 115.6%; Δ 0.42pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.20 (>3.0%) and CFO 22.2m > Net Income 6.25m (YES >=105%, WARN >=100%)

Net Debt (-63.7m) to EBITDA (8.79m) ratio: -7.25 <= 3.0 (WARN <= 3.5)

Current Ratio 3.19 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (19.0m) change vs 12m ago 13.94% (target <= -2.0% for YES)

Gross Margin 74.92% (prev 74.57%; Δ 0.34pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 53.03% (prev 53.58%; Δ -0.55pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 2.33 (EBITDA TTM 8.79m / Interest Expense TTM 3.00m) >= 6 (WARN >= 3)

Altman Z'' -1.08

(A) 0.50 = (Total Current Assets 82.9m - Total Current Liabilities 26.0m) / Total Assets 113.1m

(B) -0.83 = Retained Earnings (Balance) -93.7m / Total Assets 113.1m

(D) -2.09 = Book Value of Equity -89.8m / Total Liabilities 43.0m

Total Rating: -1.08 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 76.20

1. Piotroski 5.0pt

2. FCF Yield 7.21%

3. FCF Margin 37.37%

4. Debt/Equity 0.10

5. Debt/Ebitda -7.25

6. ROIC - WACC (= -0.21)%

7. RoE 9.46%

8. Rev. Trend 78.38%

9. EPS Trend 73.79%

What is the price of BWAY shares?

As of December 25, 2025, the stock is trading at USD 19.29 with a total of 40,805 shares traded.
Over the past week, the price has changed by +18.71%, over one month by +28.39%, over three months by +29.38% and over the past year by +106.31%.

Is BWAY a buy, sell or hold?

Brainsway has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy BWAY.

Strong Buy: 3
Buy: 1
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the BWAY price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	22	14%
Analysts Target Price	22	14%
ValueRay Target Price	23.2	20.2%

BWAY Fundamental Data Overview December 19, 2025

Market Cap USD = 318.1m (318.1m USD * 1.0 USD.USD)
P/E Trailing = 52.4194
P/E Forward = 44.4444
P/S = 6.48
P/B = 4.7137
Beta = 0.272
Revenue TTM = 49.1m USD
EBIT TTM = 6.97m USD
EBITDA TTM = 8.79m USD
Long Term Debt = 6.75m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.04m USD (from shortTermDebt, last quarter)
Debt = 6.75m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -63.7m USD (from netDebt column, last quarter)
Enterprise Value = 254.4m USD (318.1m + Debt 6.75m - CCE 70.5m)
Interest Coverage Ratio = 2.33 (Ebit TTM 6.97m / Interest Expense TTM 3.00m)
FCF Yield = 7.21% (FCF TTM 18.3m / Enterprise Value 254.4m)
FCF Margin = 37.37% (FCF TTM 18.3m / Revenue TTM 49.1m)
Net Margin = 12.73% (Net Income TTM 6.25m / Revenue TTM 49.1m)
Gross Margin = 74.92% ((Revenue TTM 49.1m - Cost of Revenue TTM 12.3m) / Revenue TTM)
Gross Margin QoQ = 75.19% (prev 75.20%)
Tobins Q-Ratio = 2.25 (Enterprise Value 254.4m / Total Assets 113.1m)
Interest Expense / Debt = 8.46% (Interest Expense 571.0k / Debt 6.75m)
Taxrate = 13.38% (242.0k / 1.81m)
NOPAT = 6.04m (EBIT 6.97m * (1 - 13.38%))
Current Ratio = 3.19 (Total Current Assets 82.9m / Total Current Liabilities 26.0m)
Debt / Equity = 0.10 (Debt 6.75m / totalStockholderEquity, last quarter 70.1m)
Debt / EBITDA = -7.25 (Net Debt -63.7m / EBITDA 8.79m)
Debt / FCF = -3.47 (Net Debt -63.7m / FCF TTM 18.3m)
Total Stockholder Equity = 66.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.53% (Net Income 6.25m / Total Assets 113.1m)
RoE = 9.46% (Net Income TTM 6.25m / Total Stockholder Equity 66.1m)
RoCE = 9.57% (EBIT 6.97m / Capital Employed (Equity 66.1m + L.T.Debt 6.75m))
RoIC = 9.14% (NOPAT 6.04m / Invested Capital 66.1m)
WACC = 9.35% (E(318.1m)/V(324.9m) * Re(9.39%) + D(6.75m)/V(324.9m) * Rd(8.46%) * (1-Tc(0.13)))
Discount Rate = 9.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 6.93%
[DCF Debug] Terminal Value 77.19% ; FCFE base≈13.4m ; Y1≈16.5m ; Y5≈28.2m
Fair Price DCF = 19.20 (DCF Value 375.8m / Shares Outstanding 19.6m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 73.79 | EPS CAGR: 7.31% | SUE: -0.64 | # QB: 0
Revenue Correlation: 78.38 | Revenue CAGR: 13.26% | SUE: 2.19 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.04 | Chg30d=+0.000 | Revisions Net=+2 | Analysts=2
EPS next Year (2026-12-31): EPS=0.29 | Chg30d=+0.023 | Revisions Net=+3 | Growth EPS=+67.3% | Growth Revenue=+24.1%

Additional Sources for BWAY Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle